a study to investigate combination treatment of nilotinib and pegylated interferon a2b in patients with a suboptimal molecular response after at least two years of imatinib treatment

Phase 1

• Conditions: Chronic myeloid leukemia in chronic phase and = 2 years on Imatinib treatment with suboptimal molecular response (BCR-ABL level above 0.01% IS).; MedDRA version: 17.0Level: LLTClassification code 10009700Term: CMLSystem Organ Class: 100000004864; Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]

• Registration Number: EUCTR2012-004321-25-SE
• Lead Sponsor: VU University Medical Center

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2013-02-26
• Last Update Posted: 10 December 2018

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

1.Patients =18 years of age.
2.At diagnosis chronic myeloid leukemia in chronic phase.
3.Persistent disease demonstrated by two PCR positive tests (i.e. BCR ABL level above 0.01% IS) which have been performed during the past 9 months and more than 10 weeks apart. One of these should be performed within 1 month of registration.
4. Treatment with imatinib = 600 mg for at least 2 years.The dose must have been stable in the previous 6 months and, before that, may not have exceeded 600 mg because of pre-existent hematologic, cytogenetic or molecular resistance .
5. No other current or planned anti leukemia therapies.
6. ECOG Performance status 0,1, or 2.
7. Adequate organ function as defined by:
8. Total bilirubin <1.5 x ULN (ULN = local lab upper limit of normal). Does not apply to patients with isolated hyperbilirubinemia (e.g. Gilbert’s disease) grade <3.
9. ASAT and ALAT <2.5 x ULN.
10. Serum amylase and lipase =1.5 x ULN.
11. Alkaline phosphatase =2.5 x ULN.
12. Creatinine clearance >30 ml/min.
13. Mg++, K+ =LLN.
14. Life expectancy of more than 12 months in the absence of any intervention
15. Patient has given written informed consent to participate in the study.

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 36
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 24

Exclusion Criteria

1. Prior accelerated phase or blast crisis.
2. Patient has received another investigational agent within last 6 months.
3. Previous treatment with nilotinib or dasatinib.
4. Prior stem cell transplantation.
5. Impaired cardiac function including any one of the following:
a) Inability to monitor the QT/QTc interval on ECG.
b) Long QT syndrome or a known family history of long QT syndrome.
c) Clinically significant resting brachycardia (<50 beats per minute).
d) QTc >450 msec on baseline ECG (using the QTcF formula). If QTcF >450 msec and electrolytes are not within normal ranges, electrolytes should be corrected and then the patient re screened for QTc.
e) Myocardial infarction within 12 months prior to starting study.
f) Other clinically significant uncontrolled heart disease (e.g. unstable angina, congestive heart failure or uncontrolled hypertension).
g) History of or presence of clinically significant ventricular or atrial tachyarrhythmias.
6. Known atypical BCR ABL transcript not quantifiable by standard RQ PCR
7. Presence of cardiovascular risk factors: history of cardiovascular events, like myocardial infarction, peripheral vascular disease, stroke or transient ischemic attacks; untreated hypertension; untreated hypercholesterolemia (and corresponding with a 10 year cardiovascular disease risk of = 7.5%, see http://www.patient.co.uk/doctor/cardiovascular-risk-calculator for estimation of CVD risk); smoking, when patient refuses to quit; poorly controlled diabetes mellitus (i.e. HbA1c >9.0% (>75 mmol/mol)) or clinically relevant diabetic complications such as neuropathy, retinopathy, nephropathy, coronary or peripheral vascular disease.
8. History of active malignancy during the past 5 years with the exception of basal carcinoma of the skin or carcinoma in situ of cervix uteri or breast.
9. Acute liver disease or cirrhosis.
10. Previous or active acute or chronic pancreatic disease.
11. Another severe and/or life threatening medical disease.
12. History of significant congenital or acquired bleeding disorder unrelated to cancer.
13. Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of study drug.
14. Patients actively receiving therapy with strong CYP3A4 inhibitors and the treatment cannot be either discontinued or switched to a different medication prior to starting study drug.
15. Patients who are currently receiving treatment with any medications that have the potential to prolong the QT interval and the treatment cannot be either discontinued or switched to a different medication prior to starting study drug.
16. Patients who are:
a) pregnant.
b) breast feeding.
c) of childbearing potential without a negative pregnancy test prior to baseline.
d) male or female of childbearing potential unwilling to use contraceptive precautions throughout the trial (post menopausal women must be amenorrheic for at least 12 months to be considered of non childbearing potential).
17. Interruption of imatinib therapy for a cumulative period in excess of 21 days in the preceding 3 months.
18. Major toxicity on imatinib in past 3 months.
19. History of non compliance, or other inability to grant informed consent.
20. Past or present history of alcohol abuse, use of illicit drugs, or severe psychiatric disorders, including depression.
21. Known hypersensitivity to any interferon preparation
22. Autoimmune hepatitis or a history of autoimmune disease
23. Pre exis

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified